UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of August 2021
001-39479
(Commission File Number)
Akumin Inc.
(Exact name of Registrant as specified in its charter)
8300 W. Sunrise Boulevard
Plantation, Florida 33322
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibit Index
Exhibit No. |
Description |
|
99.1 | Press Release dated August 30, 2021: Akumin Provides Bi-Weekly MCTO Status Update |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Akumin Inc. | ||||||
Date: August 30, 2021 | By: |
/s/ Matt Cameron |
||||
Matt Cameron Senior Vice President and General Counsel |
Exhibit 99.1
AKUMIN PROVIDES BI-WEEKLY MCTO STATUS UPDATE
Plantation, FL August 30, 2021 Akumin Inc. (NASDAQ/TSX: AKU) (Akumin ) is providing this update on the status of the management cease trade order granted by the Ontario Securities Commission (the OSC), as principal regulator of Akumin, on August 20, 2021 (the MCTO) under National Policy 12-203 Management Cease Trader Orders (NP 12-203). The MCTO was granted following Akumins application to the OSC once it was determined it was not in a position to file its interim financial report for the quarter ended June 30, 2021 along with the related managements discussion and analysis and CEO and CFO certificates (collectively, the Required Reports) by the reporting deadline of August 16, 2021, as initially announced on August 15, 2021 (the Default Announcement). The management cease trade order prevents the officers and/or directors named in the order from trading in Akumins securities but does not affect the ability of other shareholders, including the public, to trade in securities of Akumin.
Akumin is continuing to work to complete the preparation of the analysis to conclude and facilitate the review of the Required Reports at the earliest possible date and currently expects to be in a position to file the Required Reports within 60 days of the original filing deadline, being October 15, 2021.
Akumin confirms that since the date of the Default Announcement: (i) there has been no material change to the information set out in the Default Announcement that has not been generally disclosed; (ii) there has been no failure by Akumin in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (iii) there has not been any other specified default by Akumin under NP 12-203; and (iv) there is no other material information concerning the affairs of Akumin that has not been generally disclosed.
Akumin confirms that it will continue to satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the above-noted filing requirements.
About Akumin Inc.
Akumin Inc. is a leading provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States with a network of 137 owned and/or operated imaging centers located in Florida, Texas, Pennsylvania, Delaware, Illinois, Kansas, Georgia, and Massachusetts. By combining our clinical expertise with the latest advances in technology and information systems, our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, minimizing the cost and amount of care for patients. Our imaging procedures include MRI, CT, positron emission tomography (PET), ultrasound, diagnostic radiology (X-ray), mammography, and other interventional procedures. For more information, visit www.akumin.com.
For more information relating this press release, please contact:
R. Jeffrey White
Investor Relations
1-866-640-5222
jeffrey.white@akumin.com
Forward Looking Information
Certain statements contained in this press release may constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words could, intend, expect, believe, will, projected, estimated, proposed and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Akumins current belief or assumptions as to the outcome and timing of such future events. In particular, this release contains forward-looking information relating to the anticipated filing of the Required
Reports and Akumins intentions to continue to satisfy the provisions of the alternative information guidelines under NP 12-203. Such forward-looking information are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including, but not limited to, the risks described in greater detail in the Risk Factors section of Akumins Annual Information Form dated March 31, 2021, which is available at www.sedar.com and www.sec.gov. These risks are not intended to represent a complete list of the risks that could affect Akumin; however, these risks should be considered carefully. Further, various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Akumin. The forward-looking information contained in this release is made as of the date hereof and Akumin is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
The TSX has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.
# # #
- 2 -